Xeris secures FDA approval for Gvoke VialDx for x-ray exams

AuntMinnie.com staff writers
Mar 18, 2025

Biopharma firm Xeris has received U.S. Food and Drug Administration (FDA) approval for its liquid glucagon Gvoke VialDx to be used as a diagnostic aid during abdominal radiologic examinations.

GVoke Vial Dx is primarily indicated as an antihypoglycemic agent for subcutaneous use for the treatment of severe hypoglycemia in adult and pediatric patients two years and older with diabetes.

In addition, Xeris said that it has made an agreement with American Regent in which Xeris will be responsible for the production of Gvoke VialDx, while American Regent will be responsible for its commercialization in the U.S.

Gvoke VialDx is expected to become available in the third quarter of 2025, the company added.

Latest in Regulatory
Fda Logo V2 Social
FDA greenlights Telix NDA for prostate imaging agent Gozellix
March 21, 2025
Acr2 67d1c8899473b
ACR cautions in light of regulatory break on ownership reporting
March 14, 2025
Acr Logo 2023 400
ACR spotlights 2025 scope of practice bills
February 21, 2025
Ge Hc Logo 400
GE HealthCare secures 510(k) for updated Voluson Expert ultrasound
January 28, 2025
Related Stories
Fda Logo
FDA
FDA issues draft guidance for optical imaging drugs
Prostate Imaging2
Molecular Imaging
PSMA-PET imaging spiked after FDA approval
Back Spine Skeleton 400
Regulatory
Radiology societies challenge Wash. VKS noncoverage decision
Fda Button 400
FDA
Subtle Medical gets FDA clearance, launches MRI software suite
More in Regulatory
FDA greenlights Telix NDA for prostate imaging agent Gozellix
By AuntMinnie.com staff writers
The U.S. Food and Drug Administration (FDA) has approved a new drug application (NDA) for Telix's TLX007-CDx for prostate cancer imaging.
March 21, 2025
Fda Logo V2 Social
ACR cautions in light of regulatory break on ownership reporting
By AuntMinnie.com staff writers
The U.S. Department of Treasury will not enforce the Corporate Transparency Act come March 21, but the underlying law remains in effect.
March 14, 2025
Acr2 67d1c8899473b
ACR spotlights 2025 scope of practice bills
By AuntMinnie.com staff writers
Legislators in numerous U.S. states will be considering scope of practice bills in 2025, according to the ACR's government relations team.
February 21, 2025
Acr Logo 2023 400
GE HealthCare secures 510(k) for updated Voluson Expert ultrasound
By AuntMinnie.com staff writers
Enhancements support AI in women's imaging, particularly in complex, high-risk pregnancies.
January 28, 2025
Ge Hc Logo 400
Median Technologies extends cash runway by $50M
By AuntMinnie.com staff writers
The company's lung cancer screening software as a medical device is on track for U.S. FDA regulatory approval in Q2.
January 24, 2025
Business Graph Money Stocks
FDA issues guidance on scanning interference with implanted medical devices
By AuntMinnie.com staff writers
The FDA has received some reports of electronic medical devices being damaged during CT scans.
October 25, 2024
Fda Logo
Telix files for Nasdaq listing, posts Q3 update
By AuntMinnie.com staff writers
Telix Pharmaceuticals has filed with the U.S. Securities and Exchange Commission to list its ordinary shares and trade on the Nasdaq exchange.
October 18, 2024
Ame 2018 12 11 00 02 7009 Atom Nuclear Lab 400
RSNA offers clinical trials methodology workshop
By AuntMinnie.com staff writers
The RSNA will hold a free, six-day clinical trials methodology workshop in January 2025.
October 15, 2024
Clinical Trial Data Network 400
MITA urges 'one stability, one facility' with PET drug inspections
By AuntMinnie.com staff writers
The Medical Imaging and Technology Alliance (MITA) has responded to the U.S. FDA's change in policy on radiopharmaceutical manufacturer inspections.
October 4, 2024
Ame 2018 12 11 00 02 7009 Atom Nuclear Lab 400
FDA approves flurpiridaz F-18 PET tracer for imaging heart disease
By Will Morton
The U.S. Food and Drug Administration (FDA) approved the radiotracer flurpiridaz F-18 September 27 for PET imaging of coronary artery disease.
September 27, 2024
Fda
ACR responds to Congressional query on AI reimbursement
By Liz Carey
ACR CEO William Thorwarth Jr., MD, issued a nine-page letter to Congress on how to solve the reimbursement problem for AI in healthcare.
May 9, 2024
Washington Dc Capitol Social
FDA defines 'transparency' for AI medical devices
By Will Morton
The U.S. Food and Drug Administration (FDA) has sketched out details to help improve the transparency of AI software product information.
February 1, 2024
Question
Page 1 of 300
Next Page